Muhammad Kashif

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: CANCER MEDICINE. 2023;12(22):20736-20744
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Nahi H; Afram G; Uttervall K; Lockmer S; Tatting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: CELL REPORTS. 2023;42(8):112961
A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis
Yao H; Chen X; Wang T; Kashif M; Qiao X; Tuksammel E; Larsson L-G; Okret S; Sayin VI; Qian H; Bergo MO
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: REDOX BIOLOGY. 2023;60:102619
ROS-lowering doses of vitamins C and A accelerate malignant melanoma metastasis
Kashif M; Yao H; Schmidt S; Chen X; Truong M; Tuksammel E; Liu Y; Bergo MO
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754
Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Journal article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:s41-s41a
P-010: Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Mansson R; Wagner AK; Alici E
Article: ELIFE. 2021;10:e63284
A small-molecule ICMT inhibitor delays senescence of Hutchinson-Gilford progeria syndrome cells
Chen X; Yao H; Kashif M; Revechon G; Eriksson M; Hu J; Wang T; Liu Y; Tuksammel E; Stromblad S; Ahearn IM; Philips MR; Wiel C; Ibrahim MX; Bergo MO
Article: AGING CELL. 2020;19(8):e13200
Targeting RAS-converting enzyme 1 overcomes senescence and improves progeria-like phenotypes of ZMPSTE24 deficiency
Yao H; Chen X; Kashif M; Wang T; Ibrahim MX; Tuksammel E; Revechon G; Eriksson M; Wiel C; Bergo MO
Article: CELL. 2019;178(2):330-345.e22
BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis
Wiel C; Le Gal K; Ibrahim MX; Jahangir CA; Kashif M; Yao H; Ziegler DV; Xu X; Ghosh T; Mondal T; Kanduri C; Lindahl P; Sayin VI; Bergo MO
Article: ONCOTARGET. 2017;8(61):103952-103967
Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
Journal article: INTERNATIONAL JOURNAL OF MODERN EDUCATION AND COMPUTER SCIENCE. 2017;9(1):52-59
Adaptive Framework to Manage Multiple Teams Using Agile Methodologies
Jameel Qureshi MR; Kashif M
Article: BIOCHEMICAL PHARMACOLOGY. 2016;118:40-49
Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Article: SCIENTIFIC REPORTS. 2015;5:14118
In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.
Kashif M; Andersson C; Hassan S; Karlsson H; Senkowski W; Fryknäs M; Nygren P; Larsson R; Gustafsson MG
Article: MOLECULAR CANCER THERAPEUTICS. 2014;13(7):1964-1976
A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG

Alla övriga publikationer

Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2024;24:S269-S270
P-407 Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden
Luong V; Kashif M; Uttervall K; Bohlin A; Fernström AÖ; Qu Y; Lee S; Mendes J; Van Hoorenbeeck S; Franck EH; He J; Alici E; Lund J
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2024;24:S269-S270
Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden
Luong V; Kashif M; Uttervall K; Bohlin A; Fernstrom AO; Qu Y; Lee S; Mendes J; Van Hoorenbeeck S; Franck EH; He J; Alici E; Lund J
Meeting abstract: BLOOD. 2023;142:1960
A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk
Kashif M; Zhou Y; Luong V; Uttervall K; Gahrton G; Nahi H; Alici E; Lund J
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225
Response to Caravita di Toritto and Rago
Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Meeting abstract: BLOOD. 2022;140:12605-12606
Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
Uttervall K; Nahi H; Kashif M; Lemonakis K; Rosengren S; Brolin J; Lund J; Hansson M
Review: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2022;131(4):217-223
Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification
Chen X; Yao H; Andres V; Bergo MO; Kashif M
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:s46-s47
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:S46-S47
PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:S41
Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy
Lockmer S; Uttervall K; Kashif M; Svard C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Editorial comment: CLINICAL CHEMISTRY. 2021;67(10):1309-1311
Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma
Kashif M; Alici E; Nahi H
Conference publication: 2009;:389-394
Seamless Long Term Learning in Agile Teams for Sustainable Leadership
Qureshi MRJ; Kashif M

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI